- Home
- IMRN vs RDHL Comparison
IMRN vs RDHL Comparison
Compare IMRN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- RDHL
- Stock Information
- Founded
- IMRN 1994
- RDHL 2009
- Country
- IMRN Australia
- RDHL Israel
- Employees
- IMRN N/A
- RDHL N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- RDHL Health Care
- Exchange
- IMRN Nasdaq
- RDHL Nasdaq
- Market Cap
- IMRN 9.2M
- RDHL 3.8M
- IPO Year
- IMRN N/A
- RDHL N/A
- Fundamental
- Price
- IMRN $1.70
- RDHL $2.02
- Analyst Decision
- IMRN Strong Buy
- RDHL
- Analyst Count
- IMRN 1
- RDHL 0
- Target Price
- IMRN $5.00
- RDHL N/A
- AVG Volume (30 Days)
- IMRN 24.0K
- RDHL 19.8K
- Earning Date
- IMRN 07-07-2025
- RDHL 04-10-2025
- Dividend Yield
- IMRN N/A
- RDHL N/A
- EPS Growth
- IMRN N/A
- RDHL N/A
- EPS
- IMRN N/A
- RDHL N/A
- Revenue
- IMRN $4,048,286.00
- RDHL $8,042,999.00
- Revenue This Year
- IMRN N/A
- RDHL $381.91
- Revenue Next Year
- IMRN N/A
- RDHL N/A
- P/E Ratio
- IMRN N/A
- RDHL N/A
- Revenue Growth
- IMRN 82.90
- RDHL 23.17
- 52 Week Low
- IMRN $1.50
- RDHL $1.71
- 52 Week High
- IMRN $2.87
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- IMRN 35.44
- RDHL 56.71
- Support Level
- IMRN $1.82
- RDHL $1.75
- Resistance Level
- IMRN $1.96
- RDHL $2.08
- Average True Range (ATR)
- IMRN 0.11
- RDHL 0.10
- MACD
- IMRN -0.01
- RDHL 0.02
- Stochastic Oscillator
- IMRN 7.50
- RDHL 82.42
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.